Previously, B7-H3 (CD276), a member of the B7 family of immunoregulators18,19, was found to be specifically overexpressed in the four molecular subtypes of breast cancer (luminal A, luminal B, HER2-enriched and triple-negative), and insignificantly expressed in benign epithelium and various fibrocystic changes15. Here, CD276 is linked to breast carcinoma.